solid growth vertex cystic fibrosi therapi share
updat forecast estim jul
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research aug
estim jul
price data aug
rate updat aug
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
vertex known discov incivek blockbust
hepat drug overshadow vertex robust cystic
fibrosi franchis megablockbust potenti approv
treatment kalydeco orkambi symdeko allow vertex target
cf popul label expans
pipelin triplet like expand elig patient popul
expect vertex maintain domin
posit cystic fibrosi given strong efficaci therapi
lengthi patent lack competit develop pipelin
candid rare indic spur growth
cystic fibrosi rare indic character progress
deadli declin lung function affect approxim
peopl world-wide sinc launch kalydeco captur
target patient popul less cf patient
specif genet mutat becom backbon
combin therapi includ orkambi symdeko
pipelin triplet orkambi launch expand elig
patient popul significantli ad cf patient
homozyg mutat uptak slower
safeti profil symdeko launch didnt come
worri safeti contribut million revenu
first year target popul orkambi plu
expect peak sale billion patient
eye compani pipelin includ two tripl
combin aim target patient heterozyg
mutat compani like choos best triplet
file third quarter approv launch
year ahead brand competitor
think vertex comprehens approach alreadi shape
treatment cf earn firm domin posit
market world-wide chronic natur therapi limit
competit horizon heighten market attract
given posit market dynam think vertex cf
program could grow billion within forecast period
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
discov develop small-molecul drug
treatment seriou diseas key drug kalydeco orkambi
symdeko cystic fibrosi addit sever pipelin candid
target market vertex pipelin also includ therapi cancer
pain inflammatori diseas influenza rare diseas
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
solid growth vertex cystic fibrosi therapi
result
maintain fair valu estim narrow-moat
rate base intang asset
under-valued believ investor wait wider
margin safeti consid narrow-moat
vertex portfolio compos three key drug cystic
fibrosi kalydeco orkambi symdeko earn total
revenu million second quarter repres
increas come slightli ahead
estim new growth larg came symdeko
launch contribut million
second quarter orkambi sale
partial cannib symdeko success total
million kalydeco vertex earliest therapi
contribut million orkambi kalydeco grew
low singl digit year year expect
patient orkambi symdeko switch
triple-combin therapi pend approv
triple-combin regimen could approv
earli first-quart grant prioriti review
approv tripl combin key driver
growth expect compani
adjust oper expens tick slightli
adjust oper margin expand nice
compar expect research
develop cost ramp dollar basi
next sever year vertex dive area outsid
cystic fibrosi support futur growth margin
continu expand top line grow
manag rais revenu guidanc full year
slightli maintain guidanc adjust oper
cost slightli increas revenu forecast
compani cf franchis alreadi slightli
manag previou guidanc view
compani recent announc jeffrey leiden
step presid ceo remain
execut chairman continu play role busi
develop invest relat public affair chief
medic offic reshma kewalramani succeed leiden
presid ceo eight month believ
leiden took ceo role pass
torch develop noteworthi track record
build vertex narrow moat comprehens
portfolio therapi cf patient includ tripl
combin pend approv join vertex
kewalramani spent decad
believ well-suit lead vertex expand
outsid cf compani said long-plan
leadership transit anticip non-disrupt
changeov
vertex sever program way outsid cf
beta thalassemia duchenn muscular dystrophi
kidney diseas like vertex focu
genet diseas approv therapi
think pipelin success area would
support narrow moat along cf franchis
program fairli earli stage possess
signific weight model current prudent
vertex begin extend reach outsid cf
order support futur growth
increas fair valu estim
larg rais likelihood tripl
combin approv follow strong
data late earli vertex cystic fibrosi
franchis remain key driver valuat
growth come continu ramp-up symdeko
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
price outsid
believ kalydeco peak sale reach
pipelin contribut modestli mid-cycle sale
million probability-adjust sale
come cancer influenza
pain cf vertex sever preclin
early-stag candid contribut valuat
yet result earli stage includ gene therapi
program beta-thalassemia sickle-cel diseas
assum oper expens grow midsingl
digit throughout forecast vertex continu cystic
fibrosi commerci strategi push pipelin
clinic trial robust product sale expand
mid-cycle oper margin compar
return invest capit peak
due strong posit cystic fibrosi off-set
vulner potenti competit bull case
model higher probabl approv vertex pipelin
includ gene therapi candid blockbust
potenti rare indic assum tripl
combin command higher price power
base case gain share quickli heterozyg
popul scenario mid-cycle sale surpass
billion compar billion base case
compani oper margin bull-cas fair
valu estim return invest capit peak
bear case assum tripl combin face
price pressur launch lower price global
triplet take longer gain traction
heterozyg patient popul scenario mid-cycle
sale billion oper margin
tezacaftor kalydeco launch
potenti tripl combin could launch
symdeko orkambi lumacaftor kalydeco approv
target homozyg patient
make cf popul
two therapi assum averag net price
 outsid
believ peak sale opportun billion
homozyg patient popul
tripl combin would target homozyg
heterozyg patient cf patient
model chanc approv net price
peak sale opportun billion
heterozyg popul
monotherapi kalydeco origin approv target
patient gate mutat
cf patient popul believ drug
larg reach satur smaller subset patient
model low-single-digit growth assum net
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
approxim bear-cas fair valu estim
peak return invest capit
throughout explicit
vertex portfolio patent-protect cystic fibrosi
first-mov statu rare indic signific
patient share believ like
vertex abl earn excess return next
year vertex market drug kalydeco orkambi
symdeko disease-modifi drug
market like soon join compani
pipelin tripl combin therapi could expand
elig patient popul significantli approv
portfolio make backbon cystic fibrosi therapi
support strong price power
intang asset key moat sourc vertex
compani benefit patent protect
cystic fibrosi therapi vertex abl build upon
intellectu properti roll better medicin
combin increasingli captur patient
kalydeco approv cf patient one copi
mutat quickli pick label expans
addit mutat age group expand
elig patient popul patient
 first approv orkambi
approv patient two copi
common mutat expand elig patient
popul significantli global
end symdeko approv target
patient popul orkambi help vertex captur
addit patient share due better efficaci
portfolio cf first mover vertex address
patient roughli global cf patient late
earli vertex reveal top-lin result
two phase combin cf patient one copi
mutat like expans current
label combin new triplet approv would
increas elig patient popul
roughli cf patient
vertex strategi build upon kalydeco symdeko
orkambi doublet combin add cftr
corrector kalydeco cftr potenti pipelin
candid mention tripl combin
symdeko new cftr corrector
deliv promis data compani choos
promis triplet move forward regulatori
file uniqu dynam addit molecul
result new efficaci therapi serv
competit advantag vertex entrench
therapi cystic fibrosi treatment lengthen
period patent protect mani pipelin competitor
studi candid combin one
vertex molecul illustr vertex posit
backbon treatment option
cystic fibrosi rare chronic condit without
command strong price power mani patient start
treatment earli childhood continu lifetim
estim kalydeco vertex first cf therapi
list price monotherapi target
cf patient orkambi symdeko
doublet treat much larger portion cf patient
far behind six-figur price tag
strong efficaci price power vertex cystic fibrosi
portfolio potenti contribut billion
sale compar billion
vertex face signific competit cystic
fibrosi market opinion galapago partnership
previous closest competitor
report lacklust phase result lead candid
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
intang asset
illustr high bar efficaci vertex portfolio
led partner initi step away
trial acquir galapago cf pipelin
octob still unclear intent
candid see viabl threat
competitor proteostasi doublet
triplet well one candid combin
vertex therapi report disappoint data
first quarter sever year behind vertex
believ vertex benefit posit moat trend
rate base recent approv promis pipelin
like support domin posit cystic
fibrosi compani demonstr lucr
develop strategi build upon kalydeco
doublet orkambi symdeko well potenti
tripl combin next five year estim
compani could treat elig patient
patient share increas driven symdeko approv
futur tripl potenti approv
potenti approv tripl combin add
posit trend rate lengthen possibl patent
protect lack close competit also
support posit trend rate give vertex room
take tripl combin across finish line thu
significantli expand elig patient popul
includ cystic fibrosi patient
given earli statu assign much weight
opportun earli pipelin candid focu
beta-thalassemia sickle-cel diseas line
compani core focu later-stag candid
oncolog partner merck influenza partner
johnson johnson pain look promis
would add diversif vertex strengthen base
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
ocyst fibrosi main driver vertex valuat
compani could fail diversifi
opric pressur could erod return given high
price tag vertex therapi
ogen edit program could disrupt vertex hold
cystic fibrosi market
oth firm cystic fibrosi therapi pois
domin lucr market forese
futur base disease-modifi potenti
drug chronic use patient limit
lead drug candid mostli
discov in-hous lend credibl drug-
discoveri technolog potenti gener
overtex combin therapi lengthi patent
protect profit cystic fibrosi portfolio
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
believ vertex fair financi health given strong
cash flow gener reason debt year-end
vertex billion cash invest
million debtlik leas oblig like
biotechnolog compani earli stage vertex
histor oper loss high cost
clinic trial research loss financ
larg offer equiti debt secur
collabor fund arrang develop
mileston royalti partner howev
launch orkambi kalydeco compani
abl gener signific revenu allow
build signific cash cushion suffici fund
develop commerci remain
development-stag candid launch
symdeko like launch tripl combin
believ compani continu oper sustain
profit level throughout explicit forecast expect
vertex mostli use cash build
diversifi rare-diseas portfolio look beyond
cystic fibrosi market cash gener cystic
fibrosi portfolio continu expect compani
return capit sharehold via share buyback
believ vertex merit medium uncertainti rate
lack diversif off-set strong posit
cystic fibrosi lack competit compani
valuat driven cystic fibrosi franchis growth
larg depend tripl combin success
price power fair level uncertainti
think lack close competit
strong cash gener medium term provid solid
cushion risk relianc cystic fibrosi
assumpt high price underpin view
blockbust potenti cf market risk
price pressur payer particularli stricter regul
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
europ depress return despit vertex strong posit
competit nation health servic england
deni reimburs orkambi sinc approv
cite cost-effect concern howev
believ wide public battl orkambi
reimburs unit kingdom outlier
benefit match altern form
care risk investor awar
potenti competit compani earli pipelin
competit cystic fibrosi still fairli spars
small risk disrupt gene edit
vertex therapi disease-modifi
correct underli genet mutat howev vertex
partner crispr uncov cure year
expertis indic pipelin success especi
rare diseas orphan drug strong price
power would provid welcom diversif firm
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
ceo/chairman board/
repres date owner name posit common share held report holder issuer
american fund growth fund amer
fidel manag research compani
new york mellon corp
share
fund
share
fund
stewardship rate jeffrey leiden becam ceo
chairman experi includ role
manag director claru ventur special
life scienc capit well presid chief
oper offic experi
pharma well-suit lead vertex emerg
cash-burn stage global commerci
howev believ would serv investor better
ceo chairman role separ
join leiden manag team sever
pharma veteran come
glaxosmithklin previou cfo ian smith abruptli
termin earli person behavior
detail disclos reason
believ significantli weigh compani
think manag compens histor
high although recent measur spur sharehold
vote curtail amount go forward
leiden total compens million sever
senior manag compens packag
million leiden total compens drop
million respons sharehold disapprov
drop million compani also probe
secur exchang commiss seri
larg insid stock sale posit clinic news past
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
narrow-moat vertex sale soar symdeko
vertex first-quart result slightli ahead
expect compani strong portfolio cystic
fibrosi therapi continu support narrow econom
moat total product revenu million
last year driven reimburs price
agreement europ anticip symdeko
launch recent germani
symkevi would key driver year uptak
first quarter much better expect
maintain fair valu estim per share
narrow-moat vertex would advis investor
wait wider margin safeti medium uncertainti
kalydeco address small portion cystic
fibrosi popul monotherapi saw slight decreas
sale last year contribut
million orkambi sale million
last year off-set growth
symdeko cover similar popul offer
attract safeti profil symdeko contribut
million sale significantli million last year
sequenti maintain
estim product revenu billion
near higher end guidanc oper expens
track expect maintain full-
year estim billion oper expens
midpoint manag guidanc
first quarter beat consensu top bottom
line guidanc take account possibl
reimburs agreement major countri still
wait hear agreement england franc
negoti on-going pleas
hear agreement pediatr patient sweden
also wait hear triplet combin
therapi vertex choos file regulatori approv
approv cystic fibrosi patient heterozyg
address patient popul
cystic fibrosi patient
approv april vertex receiv first approv
cystic fibrosi infant kalydeco expand
address patient popul vertex reach
therapi expect addit label expans year
young age group could increas elig
popul patient world-wide
top-lin phase result vertex triplet
regimen releas eye vertex strategi shift
develop cystic fibrosi new indic
addit studi pain compani on-going earli
research antitrypsin defici gene edit
studi sickl cell diseas beta thalassemia
preclin work focal segment glomerulosclerosi
like focu lucr rare diseas high unmet
need competitor along develop
vy indic howev vertex research
develop strategi histor success
cystic fibrosi portfolio develop hous
early-stag pipelin candid outsid cystic
fibrosi materi contribut top-lin
project medium term compani complet
quarter billion cash equival
expect reinvest pipelin
potenti busi develop year vertex look
new market opportun outsid cystic fibrosi
increas vertex fve anticip
tripl combo launch
rais fair valu estim vertex
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
increas probabl approv tripl
combin therapi follow strong data late
earli vertex cystic fibrosi franchis remain key
driver valuat growth come
continu ramp-up symdeko launch
potenti tripl combin could launch
approv vertex strong return invest capit
lengthi patent domin posit lucr
rate support intang asset
vertex market drug kalydeco orkambi symdeko
disease-modifi drug market
like soon join compani pipelin
tripl combin therapi could expand elig
patient popul cover cystic fibrosi
patient approv portfolio make standard
care cystic fibrosi therapi support strong six-
compani mani close competitor
especi disappoint data galapago
anoth competitor proteostasi therapeut
doublet triplet well one candid
combin vertex therapi howev compani
year behind vertex report disappoint data
confid vertex narrow moat
also believ compani benefit posit
moat trend base recent approv promis
pipelin like support domin posit
cystic fibrosi lack close competit also support
posit trend rate give vertex room take
tripl combin across finish line develop
pipelin asset earli pipelin candid focu rare
thalassemia sickle-cel diseas line
compani core focu later-stag candid
oncolog partner merck influenza partner
johnson johnson pain look promis
would add diversif vertex strengthen base
intang asset
symdeko launch maintain fve feb
narrow-moat vertex post product revenu
million last year sequenti thank
strong cystic fibrosi portfolio recent launch
symdeko unit state revisit model
firm file full-year result
anticip signific chang fair valu estim
point manag full-year outlook
includ revenu guidanc billion billion
mostli line expect guidanc
billion oper spend slightli
expect still reason given increas global
could provid upsid manag top-lin guidanc
includ current reimburs although
compani still hasnt reach agreement england
nation institut excel
initi reject compani offer orkambi
due high price pleas hear
progress talk regulatori bodi scotland
upcom
look ahead expect phase data tripl
combin cystic fibrosi first quarter
well phase data pain first
half approv compani tripl combin
patient popul cystic fibrosi pain repres
multipl market opportun show potenti
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
acut chronic pain model tripl
combin regimen launch global end
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
